Madrigal Pharmaceuticals Inc (MDGL)vsVertex Pharmaceuticals Inc (VRTX)
MDGL
Madrigal Pharmaceuticals Inc
$534.49
+1.04%
HEALTHCARE · Cap: $12.34B
VRTX
Vertex Pharmaceuticals Inc
$519.51
+0.79%
HEALTHCARE · Cap: $130.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 880% more annual revenue ($12.59B vs $1.28B). VRTX leads profitability with a 35.0% profit margin vs -25.3%. VRTX earns a higher WallStSmart Score of 64/100 (C+).
MDGL
Avoid31
out of 100
Grade: F
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MDGL.
Margin of Safety
+46.5%
Fair Value
$963.47
Current Price
$519.51
$443.96 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 71.2% year-over-year
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Weak financial health signals
Trading at 23.6x book value
ROE of -62.1% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MDGL
The strongest argument for MDGL centers on Revenue Growth. Revenue growth of 71.2% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : MDGL
The primary concerns for MDGL are EPS Growth, Piotroski F-Score, Price/Book.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
MDGL profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.
VRTX carries more volatility with a beta of 0.32 — expect wider price swings.
MDGL is growing revenue faster at 71.2% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 31/100), backed by strong 35.0% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Madrigal Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?